Presoaked IOLs show dual action

Article

Intraocular lenses (IOLs) soaked in antibiotics have antimicrobial properties, according to results published in the October issue of the Journal of Ocular Pharmacology and Therapeutics.

Intraocular lenses (IOLs) soaked in antibiotics have antimicrobial properties, according to results published in the October issue of the Journal of Ocular Pharmacology and Therapeutics.

Edward F. Smith of the department of ophthalmology at the State University of New York (SUNY), US and colleagues immersed six groups (each group, n=8–10) of commercially available IOLs in fourth-generation fluoroquinolones as follows: 1.8 µg/mL moxifloxacin for 60 minutes; 5 mg/mL moxifloxacin for one minute; 5 mg/mL moxifloxacin for 60 minutes; 0.48 µg/mL gatifloxacin for 60 minutes; 3 mg/mL gatifloxacin for one minute; and 3 mg/mL gatifloxacin for 60 minutes. A control group of IOLs was soaked in saline for 60 minutes. The IOLs were placed in agar with an overlay of S. aureus and after 24 hours, the team measured bacterial kill zones.

Among the groups soaked in lower-strength doses of antibiotic for 60 minutes, the 0.48 µg/mL gatifloxacin and saline produced no measurable bacterial kill zone, whereas the 1.8 µg/mL moxifloxacin group produced a bacterial kill zone of 3.88±3.18 mm. A kill zone of ≥33 mm was achieved by all groups soaked in high dose fluoroquinolones: for the 5 mg/mL moxifloxacin group (one minute), this was 38.80±3.74 mm; 3 mg/mL gatifloxacin (one minute), 34.30±1.34 mm; 5 mg/mL moxifloxacin (60 minutes), 33.56±1.42 mm; 3 mg/mL gatifloxacin (60 minutes), 33.67±0.50 mm.

Thus the researchers concluded that soaking IOLs in high (commercial) levels of fluoroquinolones produces IOLs with antimicrobial properties in vitro. The widest bacterial kill zone was achieved with IOLs immersed for one minute in 5 mg/mL of moxifloxacin.

Recent Videos
Patrick C. Staropoli, MD, discusses clinical characterisation of Hexokinase 1 (HK1) mutations causing autosomal dominant pericentral retinitis pigmentosa
Richard B. Rosen, MD, discusses his ASRS presentation on illuminating subclinical sickle cell activities using dynamic OCT angiography
ASRS 2024: Socioeconomic barriers and visual outcomes in patients with rhegmatogenous retinal detachments, from Sally S. Ong, MD
Ashkan Abbey, MD, speaks about his presentation on the the CALM registry study, the 36-month outcomes of real world patients receiving fluocinolone acetonide 0.18 mg at the annual ASRS meeting in Stockholm, Sweden.
Nikoloz Labauri, MD, FVRS, speaks at the 2024 ASRS meeting about suspensory macular buckling as a novel technique for addressing myopic traction maculopathy
Jordana Fein, MD, MS, speaks with Modern Retina about the IOP outcomes with aflibercept 8 mg and 2 mg in patients with DME through week 48 of the phase 2/3 PHOTON trial at the annual ASRS meeting in Stockholm, Sweden.
John T. Thompson, MD, discusses his presentation at ASRS, Long-Term Results of Macular Hole Surgery With Long-Acting Gas Tamponade and Internal Limiting Membrane Peeling
ASRS 2024: Michael Singer, MD, shares 100-week results from the RESTORE trial
© 2024 MJH Life Sciences

All rights reserved.